Categories: News

TransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference

ANDOVER, Mass., July 29, 2024 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Tuesday, August 13, 2024, at 9:30 a.m. Eastern Standard Time.

Event: Canaccord Genuity 44th Annual Growth Conference 
Date: Tuesday, August 13, 2024 
Time: 9:30 a.m. ET 

A live and archived webcast of the fireside chat will be available on the “Investors” section of the TransMedics website at https://investors.transmedics.com/

About TransMedics Group, Inc. 
TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact: 
Brian Johnston 
631-807-1986 
Investors@transmedics.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-302208688.html

SOURCE TransMedics Group, Inc.

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

30 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

30 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

4 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

5 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

19 hours ago